NYSEARCA:PBE Invesco Biotechnology & Genome ETF (PBE) Price, Holdings, & News → If you have $2,500 bucks… check this out (From DTI) (Ad) Free PBE Stock Alerts $61.46 +1.07 (+1.77%) (As of 11:21 AM ET) Add Compare Share Share Today's Range$61.46▼$61.4650-Day Range$59.62▼$67.2952-Week Range$52.47▼$67.76Volume938 shsAverage Volume14,445 shsMarket Capitalization$232.93 millionAssets Under Management$243.96 millionDividend Yield0.06%Net Expense Ratio0.58% Stock AnalysisStock AnalysisChartHeadlinesHoldingsOwnershipRatingsStock AnalysisChartHeadlinesHoldingsOwnershipRatings Get Invesco Biotechnology & Genome ETF alerts: Email Address About Invesco Biotechnology & Genome ETF (NYSEARCA:PBE)PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors. Invesco PowerShares Capital Management LLC acts as the Fund’s investment adviser.Read More PBE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PBE ETF News HeadlinesMarch 22, 2024 | msn.comInvesco Dynamic Biotechnology & Genome ETF declares quarterly distribution of $0.0242February 19, 2024 | investorplace.com3 Biotech Stocks to Buy That Have CRISPR-Like Breakthrough PotentialApril 29, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.February 14, 2024 | msn.comWhere Are Biotech ETFs Headed After Q4 Earnings?December 22, 2023 | uk.investing.comInvesco MSCI USA ESG Universal Screened UCITS ETF USD DistributionDecember 14, 2023 | uk.investing.comInvesco Markets plc - Invesco S&P China A 300 Swap UCITS ETFNovember 27, 2023 | lse.co.ukInvesco Nasdaq Biotech Ucits Etf Share Price (SBIO.AM)November 25, 2023 | wsj.comInvesco Biotechnology & Genome ETFApril 29, 2024 | Paradigm Press (Ad)Biden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.November 16, 2023 | lse.co.ukInvesco Msci World Esg Screen Ucits Etf Share Price (ESGW.MI)See More Headlines Receive PBE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Invesco Biotechnology & Genome ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address Fund Details IssuerInvesco Fund NameInvesco Biotechnology & Genome ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:PBE Inception Date6/23/2005 Fund ManagerPeter Hubbard, Michael Jeanette, Pratik Doshi, Tony Seisser Webwww.invescopowershares.com Phone+1-800-9830903Fund Focus Asset ClassEquity BenchmarkDynamic Biotech & Genome Intellidex Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings34 Fund Statistics Assets Under Management$243.96 million Average Daily Volume$16,608.90 Discount/Premium0.00% Administrator, Advisor and Custodian AdministratorThe Bank of New York Mellon Corporation AdvisorInvesco Capital Management LLC CustodianThe Bank of New York Mellon Corporation DistributorInvesco Distributors, Inc. Transfer AgentThe Bank of New York Mellon Corporation TrusteeN/A Lead Market MakerCitadel Options OptionableN/A Short Interest9,000 shs Miscellaneous Outstanding Shares3,790,000Beta0.92 Creation Unit10,000 Creation Fee$500.00 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Ad WealthPressThe system that called 2023’s top 7 stocks is at it again…Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.Just follow this link here! Invesco Biotechnology & Genome ETF ExpensesTypePBEHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.50%0.56%0.54%0.50%0.51%Other Expenses0.08%0.40%0.54%0.64%0.58%Total Expense0.58%0.72%0.70%0.74%0.70%Fee Waiver0.00%-0.53%-0.55%-0.68%-0.57%Net Expense0.58%0.60%0.60%0.57%0.58% Invesco Biotechnology & Genome ETF (PBE) Holdings & ExposureTop 10 PBE HoldingsNeurocrine Biosciences(NASDAQ:NBIX)Holding Weight: 5.55%Amgen(NASDAQ:AMGN)Holding Weight: 5.08%Vertex Pharmaceuticals(NASDAQ:VRTX)Holding Weight: 5.05%Regeneron Pharmaceuticals(NASDAQ:REGN)Holding Weight: 5.03%BioMarin Pharmaceutical(NASDAQ:BMRN)Holding Weight: 4.95%Biogen(NASDAQ:BIIB)Holding Weight: 4.93%Gilead Sciences(NASDAQ:GILD)Holding Weight: 4.84%Bio-Techne(NASDAQ:TECH)Holding Weight: 4.76%MannKind(NASDAQ:MNKD)Holding Weight: 3.38%Exelixis(NASDAQ:EXEL)Holding Weight: 3.32%PBE Sector ExposurePBE Industry ExposureFull Holdings Details Key ExecutivesH. Bruce BondChairman of the Board of Trustee, Chief Executive OfficerBruce T. DuncanChief Financial Officer, TreasurerKevin R. GustafsonChief Compliance OfficerKeith A OvittSecretaryRonn R. BaggeTrusteeMarc M KoleTrusteeD. Mark McMillanTrusteePhilip M. Nussbaum MbaTrusteeDonald H. WilsonTrusteeMore ExecutivesSimilar ETFsSPDR S&P Health Care Equipment ETFNYSEARCA:XHEInvesco S&P SmallCap Health Care ETFNASDAQ:PSCHInvesco Pharmaceuticals ETFNYSEARCA:PJPSPDR S&P Pharmaceuticals ETFNYSEARCA:XPHDirexion Daily Healthcare Bull 3x SharesNYSEARCA:CUREInstitutional OwnershipYHB Investment Advisors Inc.Bought 1,851 shares on 4/26/2024Ownership: 0.648%Raymond James Financial Services Advisors Inc.Bought 2,118 shares on 4/23/2024Ownership: 0.499%Massachusetts Wealth ManagementBought 2,509 shares on 4/19/2024Ownership: 0.387%Webster Bank N. A.Sold 1,470 shares on 4/16/2024Ownership: 0.048%Banque Cantonale VaudoiseBought 1,454 shares on 4/10/2024Ownership: 0.131%View All Institutional Transactions PBE ETF - Frequently Asked Questions How have PBE shares performed in 2024? Invesco Biotechnology & Genome ETF's stock was trading at $65.84 on January 1st, 2024. Since then, PBE shares have decreased by 8.3% and is now trading at $60.39. View the best growth stocks for 2024 here. What does PBE invest in? Invesco Biotechnology & Genome ETF is a equity fund issued by Invesco. PBE focuses on health care investments and follows the Dynamic Biotech & Genome Intellidex Index. The fund's investments total to approximately $243.96 million assets under management. What stocks does Invesco Biotechnology & Genome ETF hold? PBE invests in 34 holdings. Some of the stocks in their portfolio include Neurocrine Biosciences (NBIX), Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), BioMarin Pharmaceutical (BMRN), Biogen (BIIB), Gilead Sciences (GILD), Bio-Techne (TECH), MannKind (MNKD) and Exelixis (EXEL). What is the management fee for Invesco Biotechnology & Genome ETF? Invesco Biotechnology & Genome ETF's management fee is 0.50% and has other expenses of 0.08%. The net expense ratio for PBE is 0.58%. What other stocks do shareholders of Invesco Biotechnology & Genome ETF own? Based on aggregate information from My MarketBeat watchlists, some companies that other Invesco Biotechnology & Genome ETF investors own include Pfizer (PFE), Intel (INTC), Align Technology (ALGN), Micron Technology (MU), Activision Blizzard (ATVI), DocuSign (DOCU), Inovio Pharmaceuticals (INO), Mastercard (MA), Hello Group (MOMO) and ONEOK (OKE). Who are Invesco Biotechnology & Genome ETF's major shareholders? Invesco Biotechnology & Genome ETF's stock is owned by a number of institutional and retail investors. Top institutional investors include YHB Investment Advisors Inc. (0.65%), Raymond James Financial Services Advisors Inc. (0.50%), Massachusetts Wealth Management (0.39%), Banque Cantonale Vaudoise (0.13%) and Webster Bank N. A. (0.05%). How do I buy shares of Invesco Biotechnology & Genome ETF? Shares of PBE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEARCA:PBE) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsAI finds its first serious applicationWall Street StarForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportProtect Your Bank Account Before It’s Too LateWeiss RatingsTrump is sounding the alarmPreserve GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invesco Biotechnology & Genome ETF Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.